30.08.2022 • News

Lummus Wins China Projects

US licensing group Lummus Technology has won two contracts from China’s Fujian Eversun New Material to supply its Catofin technology for a 900,000 t/y propane dehydrogenation (PDH) unit and its Novolen process for an 800,000 t/y PP plant in Fujian province.

The scope of the contracts includes the technology licenses plus basic design engineering, training, services and catalyst supply. Lummus added that the Catofin plant will be the world’s largest PDH unit, alongside another in China that it licensed to Fujian Meide in May. This plant, also with capacity of 900,000 t/y, is being built in Fuzhou and is scheduled to start up in 2023. 

“Catofin and Novolen have very strong market positions due to their high reliability, lower capital and operating expenses, exceptional environmental performance and simple processes,” said Lummus president and CEO Leon de Bruyn. “In addition to these competitive and cost advantages, Fujian Eversun will benefit from Lummus’ unique integrated technology offering providing a single-point performance guarantee during the entire life cycle of both units, from the feed in to product output to ongoing operations.”    

In June, Lummus announced the commissioning and startup of another PDH unit at Shandong Ruize Chemical Technology’s complex in Zibo City, Shandong province, China. The plant also uses Catofin technology to produce 300,000 t/y propylene.

Author: Elaine Burridge, Freelance Journalist

© Shutterstock/slasha
© Shutterstock/slasha

Company

Logo:

Lummus Technology

5825 North Sam Houston Pkwy W #600
77086 Houston, TX
US

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.